Ovarian Cancer (Treatment)

Study Bolsters Therapeutic Qualities of Estrogen for Women with Ovarian Cancer

Published in Cancer Weekly, October 18th, 1999

A new study, published in the October 1999 issue of Cancer, enhances prior findings that postoperative estrogen (ovarian hormone) replacement therapy (ERT) is not associated with ovarian cancer relapse.

Researchers in Johannesburg, South Africa, discovered that administration of estrogen to women who had undergone surgery for ovarian cancer did not make them more susceptible to recurrence of the cancer than other patients, who did not receive the medication. Hence, ERT did not hinder the postoperative disease-free interval or the overall chances for survival. (Guidozzi, F., and Daponte, A., "Estrogen Replacement Therapy for Ovarian Carcinoma Survivors: A Randomized...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-10-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry